Volvo Financial Services ready to start business in Czech Republic
GOTEBORG, Sweden, Jan. 21, 2004 (PRIMEZONE) -- In order to provide dedicated service to the growing Eastern European markets, Volvo Financial Services announces the founding of a branch company in the Czech Republic.
Universal Stainless & Alloy Products, Inc.
Universal Stainless Names Vice President of Sales and Marketing
BRIDGEVILLE, Pa., Jan. 21, 2004 (PRIMEZONE) -- Universal Stainless & Alloy Products, Inc. (Nasdaq:USAP) today announced that Dudley J. Merchant, 48, has been named to the newly created position of Vice President of Sales and Marketing for the Company.
LONDON, Jan. 21, 2004 (PRIMEZONE) -- The cash register bells have not been ringing merrily for everybody this Christmas, but they certainly were for Binatone. A leading manufacturer of telecom equipment Binatone boasted record sales this Christmas.
Thinkpath Announces New Contract Worth $2 million
TORONTO, Jan. 21, 2004 (PRIMEZONE) -- Thinkpath Inc., (OTCBB:THTHF), a global provider of engineering solutions in engineering knowledge management, including design, build, on-site support, technical publishing, and consulting, announced a contract worth approximately US$2,000,000 with a leading global supplier of advanced automotive systems.
Force Protection, Inc. Hires VP of Sales
CHARLESTON, S.C., Jan. 21 2004 (PRIMEZONE) -- Force Protection, Inc. (OTCBB:FRCP) announced today the appointment of Michael Aldrich as Vice President of Sales. Mr. Aldrich will hold the same position in Technical Solutions Group (TSG), a wholly owned subsidiary. He will report directly to Michael Watts, the Company's CEO.
Xtreme Companies Names New Directors
STANTON, Calif., Jan. 21, 2004 (PRIMEZONE) -- Xtreme Companies, Inc. (OTCBB:XTRI) announced today that the following individuals have been named to its Board of Directors; Barrett Evans, Theodore Smith, Kevin Ryan, Douglas Leighton and Michael Novielli. Mr. Novielli was voted to the position of Chairman and Mr. Ryan is the Company's Chief Executive Officer.
Universal Stainless & Alloy Products, Inc.
BRIDGEVILLE, Pa., Jan. 21, 2004 (PRIMEZONE) -- Universal Stainless & Alloy Products, Inc. (Nasdaq:USAP) today reported fourth quarter 2003 sales of $18.8 million and a net loss of $273,000, or $0.04 per diluted share. That compares to sales of $15.9 million and a net loss of $82,000, or $0.01 per diluted share, reported in the comparable period of 2002. The fourth quarter 2002 results included other income of $310,000 or $0.03 per diluted share due to the receipt of import duties in accordance with the "Continued Dumping and Subsidy Act of 2000."
NutraCea More Than Doubles Its Revenues
EL DORADO HILLS, Calif., Jan. 21, 2004 (PRIMEZONE) -- NutraCea (OTCBB:NTRZ), a leading nutraceutical research and development company, announced today that its preliminary unaudited third and fourth quarter revenues for the six-month period ending December 31, 2003 increased by 119% to $999,452 from $456,130 for the corresponding period in 2002.
Tripep secures U.S. patent for new application for antiviral substance ribavirin
HUDDINGE, Sweden, Jan. 21, 2004 (PRIMEZONE) -- Tripep has secured a new patent, granted in the U.S. today. The patent states the discovery that ribavirin can be used to reinforce the immune defence (it functions as an adjuvant) upon vaccination with various virus antigens. The antiviral agent ribavirin has been extant for about 30 years, and is currently used for the oral treatment of chronic hepatitis C virus (HCV) liver infections or respiratory syncytial virus (RSV) infections of the respiratory tract, applications not encompassed by Tripep's new patent. In the mid-1990s, two research groups, one at the Karolinska Institute in Stockholm, Sweden, independently discovered that daily treatment with ribavirin could produce immunomodulatory effects. Continued research resulted in Tripep's researchers discovering that ribavirin can also function as a vaccine adjuvant when administered together with virus antigens. The requirements of this now-approved US patent encompass all compounds of virus antigens and ribavirin. Tripep's scientists are now preparing to publish these findings in scientific journals, and to seek licensees, such as vaccine companies. Tripep is also examining the potential of combining the findings related to this patent with Tripep's ChronVac-C(TM) and CarryVac(TM) vaccines, and those vaccines jointly developed by partly owned enterprise VLP Biotech, of the US.
Banco Comercial Portugues -- live webcast
PORTO, U.K., Jan. 21, 2004 (PRIMEZONE) -- Banco Comercial Portugues preliminary results and live audio webcast of the group's results will be available at 1500GMT on http://www.cantos.com with Antonio Rodrigues, Chief Financial Officer and Miguel Duarte, Head of Investor Relations.
